Hydroxypropyl Distarch Phosphate (E1442): A Comprehensive Reference
1. Identity and Chemical Characterization
Names, Designations, and Classification
Hydroxypropyl distarch phosphate (HDP) is a modified resistant starch. It is used as a food additive designated by INS number 1442 and is approved for use in the European Union (listed as E1442), the United States, Australia, Taiwan, and New Zealand. It is identified by the Chemical Abstracts Service (CAS) registry number 53124-00-8.
Hydroxypropyl distarch phosphate is a chemically modified starch used as a food additive, functioning primarily as a stabilizer, thickener, and binder in processed foods. It is classified as a type 4 resistant starch (RS4). The compound does not occur in nature in pure form; ordinary starch from natural sources such as potato and corn is used as the raw material for producing the additive E1442.
Structural Chemistry
Starch typically consists of two polymers of glucose: amylose, with an almost linear structure, and amylopectin, which is highly branched. In HDP, this native starch backbone is subjected to dual chemical modification. It is prepared by etherification of native food starch with propylene oxide, which substitutes hydroxyl groups with 2-hydroxypropyl ether groups, combined with esterification using phosphorus oxychloride or sodium trimetaphosphate to introduce phosphate cross-links between starch chains, and may include additional treatments such as acid, alkali, enzyme, or bleaching in accordance with good manufacturing practices.
More precisely, hydroxypropyl distarch phosphate is manufactured by treatment of a slurry or suspension of native starch in water with sodium trimetaphosphate or phosphorus chloride under alkaline conditions, followed by etherification with propylene oxide. After the appropriate extent of cross-linking and etherification are achieved, the modified starch is recovered by neutralisation with acid, washing thoroughly with water, dewatering and drying. In the preparation of distarch phosphates, treatment is limited to a maximum of 1% of sodium trimetaphosphate or up to 0.1% phosphorus oxychloride.
Physical Properties
This white to off-white powder is insoluble in cold water and organic solvents like ethanol but forms viscous colloidal solutions when dispersed in hot water. Compared to native starch, hydroxypropyl distarch phosphate displays increased hydrophilicity from hydroxypropyl groups, which lowers the pasting temperature and boosts viscosity, alongside greater rigidity from phosphate cross-links that enhance overall durability. During the manufacturing process, chemical "cross-linking" of starch molecules occurs, increasing resistance to heat, freezing, and pH changes.
Natural Sources and Raw Material Origins
HDP is derived from natural starch sources such as maize, wheat, potato, or tapioca, which are then chemically treated to enhance functional properties. If wheat starch is used as the starting material, this must be additionally stated in accordance with EU labelling regulations, for example as "Hydroxypropyl Distarch Phosphate (Wheat)". Neither system (US or EU) generally requires the starch source — corn, wheat, potato — to be declared unless it is an allergen.
2. Traditional and Historical Use
Hydroxypropyl distarch phosphate is a product of modern industrial food chemistry and has no documented history of traditional or indigenous use. Food additive E1442 belongs to the group of modified starches, which should not be confused with genetically modified starches. Its development arose within the 20th-century food technology sector as scientists sought to enhance the functional performance of native starches. The dual modification strategy — cross-linking combined with hydroxypropylation — emerged as an industrial solution to the known limitations of native starch, including retrogradation, poor stability at high temperatures, vulnerability to acid and shear, and susceptibility to syneresis during freeze-thaw cycles.
The ever-increasing ranges of starch applications were restricted by some of its inherent adverse characteristics like retrogradability, gel opacity, low resistibility to variations of pH, and elevated shear/temperatures. Starch modification through various physical, chemical, and enzymatic methods was proposed as the most mature platform to tackle such drawbacks. Hydroxypropyl distarch phosphate was developed specifically to satisfy the demands of convenience food manufacturing, particularly within the freezer food, sauce, and dairy sectors, and has no pre-industrial analogue in any ethnobotanical or culinary tradition.
3. Key Constituents, Active Compounds, and Mechanisms of Action
Molecular Architecture
The functional identity of HDP rests on two modifications to the native starch chain: hydroxypropylation and phosphate cross-linking. During production, native starch is first reacted with propylene oxide (hydroxypropylation), which loosens the starch structure and increases water-binding capacity. A subsequent cross-linking step using phosphate bridges significantly improves thermal stability and resistance to mechanical stress.
Hydroxypropyl distarch phosphate is classified as a type 4 resistant starch due to its chemical modification through cross-linking and hydroxypropylation, rendering it resistant to enzymatic digestion in the small intestine. This can result in lower digestibility compared to native starch, ranging from 58–97% in studies.
Resistance to Digestion and Fermentation
In humans, modified starches are not absorbed intact but are significantly hydrolysed by intestinal enzymes and then fermented by the intestinal microbiota. The fraction that escapes small-intestinal digestion reaches the large intestine, where it functions as a fermentable substrate. This resistance allows undigested HDP to reach the colon, where it is fermented by gut microbiota into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. These SCFAs may support gut health by providing energy to colonocytes, modulating inflammation, and potentially improving intestinal barrier function.
For nutritional purposes, starches are classified on the basis of their rate and extent of digestion into three categories: rapidly digestible starch (RDS), slowly digestible starch (SDS), and resistant starch (RS). RDS is the starch fraction that causes a rapid increase in blood glucose level after ingestion; SDS is digested slowly but completely in the human small intestine; RS is the starch portion that cannot be digested in the small intestine, but may be fermented in the large intestine.
Gut Hormone Modulation
The aim of one human study was to investigate the effects of hydroxypropyl-distarch phosphate (HDP) supplementation on postprandial energy metabolism and glucose-dependent insulinotropic polypeptide (GIP) in human subjects. The HDP meal led to significantly lower postprandial glucose (P < 0.05), insulin (P < 0.05) and GIP (P < 0.05) responses than the waxy maize starch meal. Both postprandial resting energy expenditure (REE) and fat utilisation were negatively correlated with the postprandial GIP response, but not with the glucose and insulin responses. Dietary supplementation with HDP lowers postprandial GIP and increases postprandial REE and fat utilisation in healthy humans.
SCFA Production and Microbiota Modulation
A dose-response trial with type-IV resistant starches (RS4s) in healthy humans found that crystalline and phosphate cross-linked starch structures induce divergent and highly specific effects on microbiome composition that are linked to directed shifts in the output of either propionate or butyrate. The dominant RS4-induced effects were remarkably consistent within treatment groups, dose-dependent, plateauing at 35 g/day, and can be explained by substrate-specific binding and utilization of the RS4s by bacterial taxa with different pathways for starch metabolism.
Resistant starch acts as a prebiotic, selectively stimulating the growth of beneficial gut bacteria such as Bifidobacterium, Faecalibacterium prausnitzii, and Akkermansia muciniphila. This microbial modulation enhances SCFA production, particularly butyrate, which has been linked to anti-inflammatory effects, improved gut barrier function, and even modulation of systemic immune responses.
16S-rRNA gene sequencing in a clinical trial of RS4 revealed a differential abundance of 71 bacterial operational taxonomic units, including the enrichment of three Bacteroides species and one each of Parabacteroides, Oscillospira, Blautia, Ruminococcus, Eubacterium, and Christensenella species in the RS4 group. Gas chromatography–mass spectrometry revealed higher faecal SCFAs, including butyrate, propionate, valerate, isovalerate and hexanoate after RS4 intervention.
4. Scientific Evidence by Area of Use
4.1 Postprandial Glycemia and Insulin Response
The most studied physiological endpoint for HDP and related RS4 compounds is the attenuation of postprandial blood glucose. An acute study of maize hydroxypropyl distarch phosphate RS4 (38 g) in pancakes administered to healthy adults reported a significant reduction in postprandial glucose and insulin compared to control (0–180 min). A similarly designed study using the same RS4 (40 g) in pancakes reported no difference in blood glucose or insulin values over 180 min. It should be noted that the RS4-containing pancake in both studies provided 0 g fiber. The inconsistency between these two acute studies using the same HDP source illustrates the challenges of interpreting a small body of literature.
RS type 4, irrespective of the reason for decreased digestibility, can effectively reduce postprandial blood glucose and insulin levels when replacing the digestible carbohydrate in a food. These findings align with other acute studies of RS4, which suggests that the type of chemical modification may be less influential than previously thought.
Regarding dose-response effects, results from a randomized controlled crossover trial indicate a potential dose-response effect for RS4 on postprandial glycemia. Specifically, at the 50 g available CHO standard testing amount, RS4 reduced peak blood glucose compared to control. At the lower dose of available CHO (30 g), there was not a statistically significant beneficial effect for RS4 on postprandial glycemia.
Evidence strength: Fewer clinical studies have been conducted on resistant starch type-4, described as chemically modified starch that resists digestion by intestinal enzymes. Fewer studies have been conducted on hydroxypropyl distarch phosphate specifically — only two have been identified in the literature at the time of review. The overall evidence base for HDP specifically on glycemia is preliminary, involving acute short-term studies in small populations of healthy adults. Long-term and disease-specific trials are lacking.
4.2 Resting Energy Expenditure and Fat Metabolism
The aim of one published study was to investigate the effects of HDP supplementation on postprandial energy metabolism and glucose-dependent insulinotropic polypeptide (GIP) in human subjects. Dietary supplementation with HDP lowered postprandial GIP and increased postprandial resting energy expenditure and fat utilisation in healthy humans. An HDP-rich diet may therefore have beneficial implications in weight management. Further studies were noted as required to confirm the efficacy in overweight or obese subjects, and to determine the precise mechanisms.
RS was observed to increase postprandial resting energy expenditure (by more than 70% in the first 3 hours) and fat oxidation measured by indirect calorimetry in one human study, an effect that was coupled with a reduction in the gut hormone GIP (Shimotoyodome et al., 2011).
Evidence strength: This area of evidence for HDP specifically rests on a single human study with a small sample (n=10 per group), conducted in healthy overnight-fasted male subjects. The findings are intriguing but cannot be generalised without further replication.
4.3 Lipid Profiles and Cardiovascular Biomarkers
Clinical data on RS4 and lipid metabolism come primarily from studies using phosphated distarch phosphate (a related RS4) rather than HDP itself. A double-blind, placebo-controlled, cluster crossover intervention (n=86, age ≥18, 2–12-week interventions, 2-week washout) in the US found that RS4 consumption compared with control flour resulted in 7.2% (p=0.002) lower mean total cholesterol, 5.5% (p=0.04) lower non-HDL, and a 12.8% (p<0.001) lower HDL cholesterol in the metabolic syndrome group. Non-MetS individuals had a 2.6% (p=0.02) smaller waist circumference and 1.5% (p=0.03) lower percent body fat following RS4 intervention compared to control.
While both types of RS impacted the gut microbiota, their effects were distinct, reinforcing the hypothesis that different types of RS may yield different health effects. A study in the Hutterite community, which has a high prevalence of metabolic syndrome, demonstrated that inclusion of RS4 did not affect measures of glycemic health, but improved blood lipids, waist circumference, and body composition. The amount of RS4 or fiber consumed was not reported, which limits the ability to draw conclusions on long-term intake. An analysis of a subsample from the aforementioned study reported changes in gut microbiota composition and increased fecal short-chain fatty acid concentrations, suggesting that the gut microbiota may be a mediator for the changes in metabolic biomarkers.
Evidence strength: These long-term lipid and anthropometric data derive from studies using RS4 as a class, not HDP specifically. Extrapolation to HDP requires caution.
4.4 Gut Microbiota Modulation
Resistant starch has received considerable attention for its potential to exert a healthy impact on the gut and certain members of its resident microbiota, particularly through enhanced butyrate production. However, resistant starch is a broad category that encompasses several structurally different starches. While all resist digestion by human enzymes, they differ in their effects on the microbiota. Individual variation in microbiota composition also has a substantial influence on butyrate production.
Animal research has examined the effects of hydroxypropyl distarch phosphate of three different degrees of cross-linking on plasma cholesterol concentration, apparent digestibility of protein, fecal excretion of bile acids, fecal output, and cecal pool of organic acids. Rats were fed a fiber-free, purified diet containing either hydroxypropyl potato starch (HPS), HDP, or plain potato starch (100 g/kg) for 21 days. In each experiment, fecal output was greater and fecal excretion of bile acids was higher in rats fed the HPS diets with higher degrees of substitution and the HDP diets compared with control rats. These are preclinical data and cannot be directly extrapolated to humans.
An in vivo and in vitro study found that hydroxypropyl oxide (oxidized hydroxypropyl starch) had a prebiotic effect on the intestine, with bioinformatics showing that the structure of the microbiota changed significantly, and in vitro and in vivo fermentation results for Bacteroides uniformis and Parabacteroides distasonis showing an upward trend.
Evidence strength: Direct human clinical trial data on the specific effects of HDP on gut microbiota composition are limited. Most supporting evidence is from related RS4 compounds, in vitro fermentation models, or animal studies.
4.5 Satiety and Appetite Regulation
Satiety ratings in response to maize hydroxypropyl distarch phosphate in pancakes (40 g) did not differ from those in the control treatment in at least one clinical evaluation. In contrast, an acid-hydrolyzed and heat-treated RS4 reduced hunger and desire to eat during the 180 min following consumption. The mechanism of action for this short-term effect is unclear and warrants further research. Additionally, long-term studies of RS4 on energy intake and weight management are needed to understand the full range of responses to consumption of this fiber.
Evidence strength: The single available acute human study did not demonstrate a satiety benefit for HDP at the tested dose of 40 g. Evidence in this area is insufficient to draw conclusions.
4.6 Bile Acid Metabolism
In a clinical trial, participants consumed approximately 12 g/day of RS4 or regular wheat starch as control, each for 12 weeks without any gastrointestinal side effects. Investigators examined the effects of RS4 intake on individual bile acid (BA) species and microbiota functional capacity in adults with metabolic syndrome. The effect of RS4 on human fecal and circulating BA was reported to remain poorly understood. This area requires dedicated studies examining HDP specifically.
5. Body Systems and Health Areas Associated with HDP
- Gastrointestinal system: Undigested HDP reaches the colon, where it is fermented by gut microbiota into SCFAs such as acetate, propionate, and butyrate, which may support gut health by providing energy to colonocytes, modulating inflammation, and potentially improving intestinal barrier function.
- Metabolic and glycemic regulation: The slow fermentation profile of resistant starches like HDP contributes to blood sugar control by attenuating postprandial glucose spikes.
- Energy metabolism: Dietary supplementation with hydroxypropyl-distarch phosphate from waxy maize starch increases resting energy expenditure by lowering the postprandial glucose-dependent insulinotropic polypeptide response in human subjects (British Journal of Nutrition, 2011).
- Cardiovascular system (indirect): Evidence from RS4 class studies suggests possible modest effects on total cholesterol, non-HDL cholesterol, and waist circumference in populations with metabolic syndrome, but HDP-specific cardiovascular clinical data are absent.
- Gut microbiome: Resistant starch has potential to exert a healthy impact on the gut and certain members of its resident microbiota, particularly through enhanced butyrate production.
6. Dosage Forms and Dosages Reported in Studies
Hydroxypropyl distarch phosphate is not used as a standalone pharmaceutical or dietary supplement product but is incorporated as a food ingredient. The following dosages have been specifically reported in published studies:
- An acute study used maize hydroxypropyl distarch phosphate RS4 at 38 g incorporated into pancakes, administered to healthy adults, and reported a significant reduction in postprandial glucose and insulin compared to control.
- A separate study used maize hydroxypropyl distarch phosphate at 40 g incorporated into pancakes.
- The Shimotoyodome et al. (2011) human crossover study compared meals containing waxy maize starch or HDP in overnight-fasted healthy male subjects, with ten subjects per group.
- A dose-response trial with RS4 compounds in healthy humans found effects to be dose-dependent, plateauing at 35 g/day.
- In one longer-term clinical trial, participants consumed approximately 12 g/day of RS4 or regular wheat starch as control, each for 12 weeks.
No standardized supplemental dose for HDP as a dietary supplement has been established by any regulatory or pharmacopeial body.
7. Regulatory Status and Manufacturing Specifications
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) has evaluated hydroxypropyl distarch phosphate as safe for use in food, assigning it no numerical acceptable daily intake (ADI) due to its breakdown into components similar to native starch. The Codex General Standard for Food Additives (GSFA, Codex Stan 192-1995) includes it in Table 3, permitting its use at levels consistent with good manufacturing practice (GMP) or quantum satis in a wide range of food categories, including dairy products, bakery goods, and processed fruits and vegetables. In the United States, hydroxypropyl distarch phosphate is affirmed as generally recognized as safe (GRAS) as a modified food starch under 21 CFR 172.892.
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) conducted a re-evaluation of the safety of hydroxypropyl distarch phosphate (E1442) and related modified starches when used as food additives. These modified starches are authorised food additives in the EU according to Annex II and Annex III to Regulation (EC) No 1333/2008.
Following a request from the European Commission, the EFSA Panel was asked to deliver a scientific opinion on the re-evaluation of 12 modified starches authorised as food additives in the EU, previously evaluated by JECFA and the Scientific Committee on Food (SCF). Both committees allocated an acceptable daily intake "not specified".
JECFA, EFSA, and the FDA have all reviewed modified food starches extensively. The modification reagents used are food-grade and controlled. Residual reagent levels in the final starch are regulated and tested.
This additive is currently approved in all four major markets — US, EU, UK, and Japan. In the US, it can be listed as "modified food starch" on labels.
8. Safety Considerations
Genotoxicity
According to EFSA, in the absence of genotoxicity data on modified starches, an evaluation of genotoxicity was performed in silico using the OECD QSAR Toolbox for Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Distarch Phosphate. No relevant structural alerts for genotoxicity were highlighted for any of the three ingredients. Based on in silico analyses, modified starches are considered not to be of genotoxic concern.
Mutagenicity
The mutagenicity of hydroxypropyl starch phosphate was examined by incubating 0, 100, 333, 1000, 3330 or 5000 µg/plate in deionized water with Salmonella typhimurium (TA98, TA100, TA135, or TA137) or Escherichia coli (WP2uvrA) with or without metabolic activation. The assay was performed in triplicate.
Long-Term Toxicology
Using the read-across approach, the EFSA Panel considered that adequate data on short- and long-term toxicity and carcinogenicity, and reproductive toxicity are available for modified starches as a class. In humans, modified starches are not absorbed intact but significantly hydrolysed by intestinal enzymes and then fermented by the intestinal microbiota.
Phosphate Intake Considerations
Because HDP contains covalently bound phosphate groups, questions have been raised regarding potential contributions to total dietary phosphate load. The free and combined phosphate, calculated as phosphorus, must not exceed 0.04% for distarch phosphate made from cereal starch according to EU purity criteria. Regulatory bodies including EFSA and the FDA have evaluated this aspect and have not identified it as a concern at established food-use levels.
Allergenicity and Labelling
If wheat starch is used as the starting material, this must be additionally stated in accordance with EU labelling regulations. Individuals with diagnosed wheat or gluten-related conditions should therefore scrutinize product labeling. Since HDP derived from corn or potato starch does not inherently carry gluten, the allergen status depends entirely on the botanical source used by the manufacturer.
Use in Special Populations: Infants
With reference to the conclusions and recommendations of the EFSA re-evaluation scientific opinion, information is sought on modified starches including hydroxypropyl distarch phosphate (E1442) regarding specifications, use levels, and technological need in foods for particular nutritional uses. The European Commission has issued calls for additional data on these modified starches, particularly regarding their use across all population groups, indicating ongoing regulatory scrutiny of their suitability in specific contexts such as infant nutrition.
Digestibility Variability
Digestibility of HDP relative to native starch can range from 58–97% in studies, indicating that the degree of modification and the starch botanical source substantially influence the amount of material that behaves as truly resistant starch. This variability complicates any uniform characterization of the compound's physiological effects.
Individual Variability in Fermentation Response
Individual variation in microbiota composition has a substantial influence on butyrate production from resistant starch. These findings highlight the role of individual microbiome variability in influencing RS fermentation and health outcomes, emphasizing the need for personalized nutrition approaches.
9. Evidence Limitations and Research Gaps
The body of human clinical evidence specifically investigating hydroxypropyl distarch phosphate — as distinct from other RS4 subtypes — is very small. Fewer studies have been conducted on hydroxypropyl distarch phosphate specifically, with only two studies identified at the time of the most recent systematic review of RS4 clinical literature. The most extensively studied RS4 compound is phosphated distarch phosphate, and findings from that literature cannot be assumed to apply directly to HDP given known differences in structural chemistry and fermentation kinetics.
Fewer clinical studies have been conducted on resistant starch type-4 as a whole. The category of RS4 is diverse, with a range of starch bases and chemical modifications existing in the food supply. These attributes can affect functionality in a food product, and digestibility and fermentability after consumption. Due to these differences, it is critical to evaluate food applications and physiological effects of each specific type of RS4.
Long-term randomized controlled trials examining HDP specifically on outcomes such as glycemic control in diabetes, cardiovascular risk reduction, gut microbiome modification, or body composition are absent from the published literature. All existing human studies have been acute, short-term, and conducted in generally healthy adults. The field awaits adequately powered, long-duration, independently replicated clinical investigations before definitive health claims can be established for HDP as a distinct compound.
References
Go back